BioVie Inc. — Form 10-Q Summary
Business context and period: Clinical-stage biotechnology company developing BIV201 (terlipressin) for cirrhosis-related ascites. The quarter ended December 31, 2017, representing the three- and six-month periods ended that date; the filing reports no revenue. The company received FDA clearance to initiate a U.S. Phase 2a trial in March 2017, entered a CRADA with the McGuire Research Institute/VA in April, and began dosing patients in September 2017. BIV201 has FDA Fast Track and Orphan Drug designations.
Financial results and position
| Metric | Three months ended Dec. 31, 2017 | Six months ended Dec. 31, 2017 | Comparable 2016 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $494,807 | $1,157,038 | $357,799 / $709,152 |
| Operating loss | $494,807 | $1,157,038 | $357,799 / $709,152 |
| Net loss | $502,682 | $1,165,523 | $357,799 / $709,141 |
| Net loss per share, basic and diluted | $0.01 | $0.01 | $0.00 / $0.01 |
- Expenses and margins: Six-month R&D was $228,695, down $27,134 year over year; professional fees were $604,414, up $418,235, primarily due to financial and strategic advisory services paid in stock. SG&A was $66,545, up $56,785, mainly from travel and conference costs related to financing. Payroll expense was $142,696. Gross margin is not applicable because there were no sales.
- Cash flow: Six-month operating cash use was $363,317, compared with $229,725 in 2016. Financing activities provided $360,001 versus $110,487. Cash declined by $3,316 to $1,824 at December 31, 2017. The cash-flow line for “proceeds from loan payable” is shown as negative $35,000, while the note says the related-party loan was repaid; verify the presentation.
- Balance sheet and liquidity: Cash was $1,824, versus $5,140 at June 30, 2017. Current liabilities were $879,218, including $629,218 of accounts payable and accrued expenses and $250,000 of accrued payroll. Long-term related-party notes payable were $575,917; total liabilities were $1,455,136. Stockholders’ equity was $791,068, down from $1,157,318. No material off-balance-sheet arrangements were reported.
Changes, outlook, and risks
- Six-month net loss widened by $456,382 year over year, and operating expenses increased by $447,886. Professional fees were the principal disclosed driver; some services were paid with shares, including 1.5 million shares valued at $330,000 for Aspire Capital services.
- The company stated that it lacked sufficient funds for planned development over the next 12 months and estimated a near-term financing need of $250,000–$500,000. It believed existing cash would not cover requirements through June 30, 2018. If financing is obtained, its estimated next-12-month spending plan was $3.0 million for R&D, $500,000 for corporate overhead, and $500,000 for staffing.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern. It planned to seek equity or debt financing and could also pursue licensing, partnerships, or other transactions. Failure to raise funds could force delayed or reduced development, licensing to third parties, or cessation of operations.
- Financing included private stock and warrant placements and an Aspire equity-line sale. At December 31, 2017, 94,971,365 common shares were outstanding; options and warrants totaled 13.781 million. A subsequent January 2018 private placement sold 333,333 shares for $50,000.
- Related-party salary and consulting obligations were deferred to December 31, 2019 under non-interest-bearing notes if paid by then; unpaid balances thereafter accrue interest at 5%. The CEO’s employment agreement provides a minimum annual base salary of $250,000. The office lease runs through December 2018 at $369 per month.
- Disclosure controls and procedures were assessed as ineffective as of December 31, 2017. Management reported no material change in internal control over financial reporting during the six-month period. The filing identifies development, regulatory, financing, and other execution risks; it gives no specific numeric clinical or regulatory milestones beyond the trial status described above.
Important facts for investors to verify
- Current cash runway, financing availability, and whether the stated $250,000–$500,000 near-term funding need was met after the reporting date.
- Phase 2a trial enrollment, progress, costs, and any subsequent safety or efficacy findings for BIV201.
- The nature and terms of related-party notes, accrued obligations, and the cash-flow statement’s negative $35,000 loan line.
- Potential dilution from outstanding options and warrants, including exercise terms, and the January 2018 share issuance.
- Remediation of the ineffective disclosure controls and any later changes in control effectiveness.